Groundbreaking Phase 3 Trial Shows Promise of Gotistobart Immunotherapy for Lung Cancer Florida Cancer Specialists' Phase 3 trial reveals that Gotistobart, a new immunotherapy, may improve outcomes for advanced lung cancer patients with fewer side effects.

Groundbreaking Phase 3 Trial Shows Promise of Gotistobart Immunotherapy for Lung Cancer #United_States #Florida_Cancer_Specialists #Fort_Myers #Lung_Cancer #Gotistobart

💫
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile

FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC - OncoDaily FDA grants Orphan Drug Designation to gotistobart for squamous NSCLC following promising overall survival benefit versus docetaxel.

FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC

@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Gotistobart

China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer OncoC4 announces that China's NMPA has granted Breakthrough Therapy Designation for Gotistobart (BNT316/ONC-392) aimed at treating squamous non-small cell lung cancer, enhancing prospects for patients facing limited options.

China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer #China #Rockville #OncoC4 #Gotistobart #BNT316